Table 3 Effective drugs for the reduction of AURKA

Drugs with significant reduction in AURKA expression post treatment

 A375

Ro-4987655

Mitogen-activated protein kinase

MEK

− 10

 A375

Genz-644282

Topoisomerase I

Topo I

− 10

 HUES3

OTS-167

Maternal embryonic leucine-zipper kinase

MELK

− 10

 HUES3

Vorinostat

Histone deacetylase

HDAC

− 10

 A375

Pralatrexate

DNA synthesis

–

− 9.838

 MCF7

Epirubicin

Topoisomerase II

Topo II

− 9.471

 HT29

Ro-4987655

Mitogen-activated protein kinase

MEK

− 9.284

 MCF7

Pralatrexate

Metabolic

–

− 9.259

 A375

JNJ-26481585

Histone deacetylase

HDAC

− 9.206

 HT29

R-547

Cyclin dependent kinase

CDK

− 8.938

Drugs with an increase in AURKA expression post treatment

 PC3

BIIB-021

Heat shock protein 90

HSP90

6.298

 HT29

NMS-1286937

Polo-like kinase 1

PLK

6.407

 HELA

NMS-1286937

Polo-like kinase 1

PLK

6.426

 HT29

Docetaxel

Microtubule function

–

6.458

 HT29

Epothilone-b

Microtubule function

–

6.518

 HT29

Indibulin

Microtubule function

–

6.552

 HELA

Dolastatin-10

Microtubule function

–

6.666

 HELA

Volasertib

Polo-like kinase 1

PLK

6.732

 HT29

Epothilone-b

Microtubule function

–

6.898

 HELA

Combretastatin-A-4

Microtubule function

–

7.007